Novogene Co Bruttokate

Mitä Novogene Co tekee? Novogene Co., Ltd. generates revenue through genomic services and solutions, primarily utilizing high-throughput sequencing and bioinformatics analysis technologies. The company offers life science basic research services, medical research and technical services, and database-building sequencing platform services, targeting both domestic and international markets. Key products include gene mutation detection kits, coronavirus disease nucleic acid test services, and DA8600 sequencers, which are sold to research institutions, medical facilities, and clinical applications. The firm's technology-driven approach enables it to provide multi-level scientific and research technical services across life science and medical fields. Novogene's revenue streams are anchored in its sequencing platforms and equipment, with the DA8600 sequencers representing a significant product line. The company develops and sells genetic testing medical equipment, leveraging its expertise in gene sequencing. Its services are tailored for life science basic research, medical and clinical applications, and database construction, serving a diverse clientele including research organizations and healthcare providers. The firm's focus on multi-omics research technology enhances its ability to deliver comprehensive solutions. The business model integrates high-throughput sequencing technology with bioinformatics analysis to create scalable services. Novogene's offerings span from basic research support to clinical diagnostic tools, with gene mutation detection kits and coronavirus disease nucleic acid test services catering to specific market needs. The company's domestic and overseas market presence ensures broad client reach, while its independent development of sequencing equipment like the DA8600 sequencers drives product-based revenue. This dual focus on services and equipment positions Novogene as a key player in genomic technology solutions. Novogene Co on yksi Eurpooliin suosituimmista yhtiöistä.